CSPC Pharmaceutical Gains NMPA Approval for Clinical Trial of mRNA Vaccine SYS6026
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...
NHSA and MoF Announce Medical Insurance Fund Prepayment Initiative to Aid Healthcare Institutions
The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MoF) have jointly issued...
InnoCare Pharma Reports 29.8% Revenue Increase in Q3 2024 Financials
Beijing-based biotech InnoCare Pharma (HKG: 9969; SHA: 688428) has released its financial report for the...
Triton Partners Mulls Acquisition of Germany’s Evotec SE, Shares Soar 22%
Private equity firm Triton Partners is reportedly contemplating the acquisition of Germany-based Evotec SE (NASDAQ:...
GenScript Biotech Expands in Australia with New Sydney Operations and Logistics Center
GenScript Biotech Corporation (HKG: 1548), a leading Chinese biotechnology company, has announced the establishment of...
Leman Biotech Secures Over USD 13.9 Million in Series A Financing for Next-Gen Cancer Immunotherapies
China-based Leman Biotech Co., Ltd. has reportedly completed the first closing of its Series A...
Biocytogen’s First-in-Class B7H3/PTK7 Bispecific ADC Option Exercised by IDEAYA Biosciences
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced that its...
Gan & Lee’s GZR18 Shows Significant Weight Loss in Phase IIb Study at ObesityWeek 2024
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the oral presentation...
J&J’s Nipocalimab Receives FDA Breakthrough Therapy Designation for Sjögren’s Disease
US-based pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that it has received...
Zai Lab and argenx Receive NMPA Approval for Vygart Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its US partner argenx SE...
Cutia Therapeutics’ CU-10201 Receives NMPA Approval for Acne Vulgaris Treatment
Cutia Therapeutics (HKG: 2487), a developer of dermatology therapies, has announced that its CU-10201, a...
BeyondSpring Presents Positive Phase II Data for Plinabulin Combination Therapy in NSCLC at SITC
BeyondSpring Inc. (NASDAQ: BYSI), a US-based biotech company, has announced the presentation of the latest...
Abbisko Therapeutics’ Pimicotinib Meets Primary Endpoint in Phase III MANEUVER Study for TGCT
hanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has revealed positive top-line results from the...
ETERN Therapeutics’ ETS-006 Receives FDA Orphan Drug Designation for Pleural Mesothelioma
ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced that it has received...
Frontera Therapeutics Receives FDA Approval for Phase II Study of FT-003 in nAMD
Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from...
Viatris Reports Q3 2024 Global Sales of USD 3.8 Billion with a 5% YOY Decline
US generics giant Viatris (NASDAQ: VTRS) has published its financial report for the third quarter...
Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies
Gilead Sciences Inc., (NASDAQ: GILD), a major US-based pharmaceutical company, has released its financial results...
GSK Leaves BIO, Joining Other Major Companies in Withdrawing Membership
GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reportedly withdrawn...
ATLATL and Takeda Enter MoU to Collaborate on Early-Stage Drug Development and Innovation
ATLATL, an innovation incubator and global life science research and development (R&D) platform, has signed...
Alteogen Secures Exclusive Licensing Deal with Daiichi Sankyo for Subcutaneous Enhertu
Alteogen Inc. (KOSDAQ: 196170), a South Korea-based biotechnology company, has announced an exclusive licensing agreement...